Clinical Trial Update: Open-label Study of Surufatinib in Japanese Patients [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/Phase 2 study of Surufatinib in Japanese patients with Neuroendocrine Tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchmed | Conditions: Neuroendocrine Tumors, Non-hematologic Malignancy | Phase 1, Phase 2 | Status: COMPLETED